640 articles
Xanthinol
Xanthinol (xanthinol nicotinate, xanthinol niacinate; CAS 2530-97-4 free base, 437-74-1 salt) is a water-soluble niacin-derivative vasodilator used for peripheral vascular insufficiency, causing flushing, gastric discomfort, and hypotension.
Ximelagatran
Ximelagatran (Exanta, Exarta) was AstraZeneca's oral prodrug of melagatran, the first oral direct thrombin inhibitor; noninferior to warfarin but withdrawn worldwide in February 2006 for hepatotoxicity.
Xl550
Xl550 is esaxerenone (CS-3150), a nonsteroidal mineralocorticoid receptor antagonist discovered by Exelixis and approved in Japan (2019) for hypertension and studied in diabetic kidney disease.
Y-shape pegylated somatropin (怡培生长激素)
Y-shape pegylated somatropin (怡培生长激素, Inpegsomatropin, brand 益佩生/Pegpesen) is Xiamen Amoytop's once-weekly 40 kD Y-shaped branched PEG-modified growth hormone, NMPA-approved May 2025 for pediatric GHD, with phase 3 noninferior growth velocity and zero anti-drug antibodies versus daily rhGH.
YS2302018
YS2302018 is CSPC Pharmaceutical's preclinical oral small-molecule lipoprotein(a) inhibitor, discovered by its AI drug design platform and exclusively licensed to AstraZeneca in October 2024 for $100 million upfront plus up to $1.92 billion in milestones.
Zalunfiban
Zalunfiban (RUC-4, Disaggpro) is an investigational subcutaneous glycoprotein IIb/IIIa inhibitor for STEMI given at first medical contact; the phase 3 CELEBRATE trial (2,467 patients) showed improved artery patency and fewer 30-day adverse outcomes without excess severe bleeding.
Zotarolimus
Zotarolimus (ABT-578), a sirolimus analog, is the antiproliferative drug in Medtronic's Endeavor, Resolute Integrity, Resolute Onyx, and Onyx Frontier coronary stents; it inhibits mTOR via FKBP12 binding.
Zovaglutide
Zovaglutide (ZT002) is an investigational once-monthly GLP-1 receptor agonist peptide injection by Beijing QL Biopharmaceutical for obesity and type 2 diabetes, in phase 3 (HORIZON-1) in China, distinguished from weekly agents like semaglutide by monthly dosing.
ZX2021
ZX2021 (GGGF-1) is a Chinese Fc-fusion triple agonist of GCGR, GIPR, and GLP-1R by Jiangsu Zhongxin Pharmaceutical, in Phase 2 for obesity and type 2 diabetes.
ZYH7
ZYH7 (ZYH-7) is an investigational PPARα agonist for dyslipidemia developed by Zydus Cadila; IND filed 2007, phase 2 trial NCT01539616 versus fenofibrate completed.